entertainment -WSS

entertainment

author：entertainment 2025-10-01 15:40:20 - browse：556

Medicare generally pays far more for CAR-T drugs that are administered in outpatient departments than it does for inpatient care. Adobe

WASHINGTON — Hospitals for years have complained that Medicare pays so little for CAR-T cancer treatments that they sometimes lose money administering the incredibly expensive treatments. But that could soon change: if drug companies succeed in making the cancer treatments safer, hospitals could provide them more often in outpatient departments, where payment is higher.

CAR-T uses the body’s own immune system to kill cancerous cells. The procedure, regulated as a drug, involves taking T cells from a patient’s blood, adding chimeric antigen receptors (CAR) to the T cells that kill cancer, and injecting the CAR-T treatment back into the patient.

It’s worked wonders in many cancer patients who have run out of options. But right now it’s almost exclusively administered in hospitals, because the side effects can require aggressive treatments. In many cases, the CAR-T cells trigger immune reactions that can be life-threatening.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

WSS

3 hurdles to bringing medical devices to the U.S. market

The science behind Janet Jackson's pregnancy at 49

CDC concerned about possible undetected monkeypox spread in U.K.

Wegovy leads to weight loss. Can it treat depression, too?

Pancreatic cancer early detection could be helped by AI

The strategy behind pharma's lawsuits over drug pricing reform

focus

entertainment

knowledge

Heart attack and stroke risk calculators need revising

Weight bias in eating disorder treatment complicated by new weight loss drugs

Duchenne breakthrough therapy leaves behind pioneering families

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The story of mRNA: From a loose idea to a tool that may help curb Covid

Supreme Court strikes down use of affirmative action

Investment in vaccine development is lagging, report finds

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

10 reasons why health care startups fail

entertainment

Do masks work? RCTs can't tell us

Cloning humans is technically possible. It's curious no one has tried

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Health Care Service Corp to buy Cigna Medicare Advantage plans

Health Care Service Corp to buy Cigna Medicare Advantage plans

Philips to halt sales of sleep apnea machines in U.S.

explore

focus

hotspot

focus